Fulcrum Therapeutics Inc
fulcrumtx.comFulcrum Therapeutics (NASDAQ: FULC) is a clinical-stage biopharmaceutical company focused on developing oral small molecules for patients with genetically defined rare diseases. The company generates no product revenue, operating entirely on capital raises to fund research and development. Its lead product candidate, pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). Fulcrum completed dosing in the Phase 1b PIONEER trial, evaluating pociredir in adults with SCD across 12 mg and 20 mg once-daily dose cohorts, and is activating sites for an open-label extension trial as of the 10-K filed February 24, 2026. Pociredir holds orphan drug designation and fast track designation from the FDA for SCD. The company plans to initiate a potential registration-enabling trial in the second half of 2026, pending FDA feedback. Fulcrum relies on contract manufacturing organizations for drug supply and third parties for clinical trial conduct. It also holds an exclusive global license agreement with CAMP4 Therapeutics Corp.
Products & Services
Pociredir: oral small molecule HbF inducer in clinical development for sickle cell disease (SCD); targets polycomb repressive complex 2 (PRC2) to reactivate fetal hemoglobin expression. Phase 1b PIONEER trial completed dosing as of the 10-K filed February 24, 2026. Orphan drug designation and fast track designation from the FDA for SCD.
Revenue Model
Fulcrum Therapeutics has no approved products and generates no product revenue. Operations are funded through capital raises. The company discloses it will need substantial additional funding to continue clinical development of pociredir and any future product candidates.
Customers & Markets
Target patient population: adults with sickle cell disease, a genetic disorder of red blood cells. No commercial customers as of the 10-K filed February 24, 2026.
Geographic Exposure
Clinical development activities span the United States (FDA engagement) and Europe (EMA engagement planned for mid-2026). No commercial geographic footprint disclosed.
Financial Snapshot
Loading...
